PA
ICL icon

PharVision Advisers’s ICL Group ICL Stock Holding History

PharVision Advisers’s Portfolio ICL Stock Details ICL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,594
Closed -$277K – 358
2025
Q4 		$277K Buy
+48,594
New +$281K 0.14% 322

Other funds holding ICL

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YDMI
Y.D. More Investments Ramat Gan, Israel $3.21B AUM 117.29% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KHLMVGHM
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return

PharVision Advisers's ICL Position: Q1 2026 in Review

PharVision Advisers sold out of ICL Group (ICL) in Q1 2026, closing a stake of 48,594 shares — an estimated $277K sold.

PharVision Advisers first reported a position in ICL in Q4 2025 and held it in 1 quarter. The position peaked at $277K in Q4 2025. 222 funds tracked by Wall St. Rank hold ICL as of Q1 2026.

  • PharVision Advisers reported no remaining ICL Group position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 48,594 ICL Group shares in Q1 2026, an estimated $277K.
  • PharVision Advisers first reported a position in ICL Group in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's ICL Group position peaked at $277K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held ICL Group as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.